Previous close | 2.3500 |
Open | 2.2700 |
Bid | 1.9700 |
Ask | 2.3300 |
Strike | 38.00 |
Expiry date | 2025-08-15 |
Day's range | 2.2700 - 2.3500 |
Contract range | N/A |
Volume | |
Open interest | 56 |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
GameStop shares continue their surge in May, a report says Arm Holdings seeks to launch its first artificial-intelligence chips next year, and Squarespace is being taken private in a deal valued at $6.9 billion.
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.